World Library  
Flag as Inappropriate
Email this Article

Sanofi-aventis

Article Id: WHEBN0004262083
Reproduction Date:

Title: Sanofi-aventis  
Author: World Heritage Encyclopedia
Language: English
Subject: Artemisinin
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Sanofi-aventis

Sanofi S.A.
Société Anonyme
Traded as 0I42, Template:FWB
Industry Pharmaceuticals
Founded 20 August 2004 (by acquisition) as Sanofi Aventis May 6, 2011 as Sanofi
Headquarters 54, rue La Boétie, 8th arrondissement, Paris, France
Key people Chris Viehbacher (CEO), Serge Weinberg (Chairman), Jean-François Dehecq (Original Founder)
Products Prescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...)
Revenue 33.38 billion (2011)[1]
Operating income €7.499 billion (2011)[1]
Profit €5.693 billion (2011)[1]
Total assets €100.16 billion (2011)[1]
Total equity €56.38 billion (2011)[1]
Employees 113,719 (2011)[1]
Subsidiaries Sanofi Pasteur
Genzyme
Shantha Biotechnics
Chattem
Zentiva
Medley
Nichi-Iko
Merial
Website

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales.[2][3] Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. The company covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).[4] Sanofi is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[5] The company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo. It changed its name to Sanofi in May 2011. In January 2012 Sanofi announced that they will invest $125 Million in Warp Drive Bio to support their cancer research program.

History

Sanofi-Synthélabo

Sanofi was founded September 10, 1973 as subsidiary of Elf Aquitaine, a French oil company, when it took control of the Labaz group, a pharmaceutical company. Its first significant venture into the U.S. market was the acquisition of the prescription pharmaceuticals business of Sterling Winthrop — an affiliate of Eastman Kodak — in 1994. Sanofi was incorporated under the laws of France in 1994 as a société anonyme , a form of limited liability company, for a term of 99 years.

Synthélabo was founded in 1970 through the merger of two French pharmaceutical laboratories, Laboratoires Dausse (founded in 1834) and Laboratoires Robert & Carrière (founded in 1899). In 1973, the French cosmetics group L’Oréal acquired the majority of its share capital.

Sanofi-Synthélabo was formed in 1999 when Sanofi (former subsidiary of Total) merged with Synthélabo (former subsidiary of L'Oréal). The merged company was based in Paris, France.

Aventis

File:Aventis logo.png

Aventis was formed in 1999 when French company Rhône-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.

Sanofi-Aventis

Sanofi-Synthélabo took control of Aventis in August 2004 and changed its registered name to “Sanofi-Aventis”. On December 31, 2004, Aventis merged with and into Sanofi-Aventis, with Sanofi-Aventis as the surviving company.

Starting in 2009, Sanofi made a series of acquisitions to create or strengthen its regional CHC and generics platforms including:

  • The Prague-based branded generics group Zentiva
  • Medley, the third largest pharmaceutical company in Brazil and a leading generics company in that country
  • Chattem, Inc., a leading U.S. consumer healthcare company.
  • BMP Sunstone Corporation
  • Genzyme Corporation, a leading biotechnology group headquartered in Cambridge, Massachusetts and specialized in the treatment of rare diseases, renal diseases, endocrinology, oncology and biosurgery.

As of the May 2011 General Meeting of Shareholders, the Group changed its name to “Sanofi

Merger and beyond

Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 billion for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 billion in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a "local solution", put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.

October 2010: Sanofi-Aventis SA laid off 1,700 US employees due to restructuring triggered by growing generic competition and other factors. The cuts were completed throughout 2011 according to transition needs. The layoffs amount to about 25 percent of the company's US pharmaceutical operation. The company denies the action was related with acquisition plan of buying US biotech firm Genzyme Corp.[6]

The company dropped the -Aventis suffix of its name on 6 May 2011 after receiving approval at its AGM. The reason given by the company for the change was to make its name easier to pronounce in countries such as China.[7]

Contaminated products and legal issues

In 1984 and 1985, the Marion institute which is now owned by Sanofi issued factors contaminated with HIV for hemophiliacs from West Germany, Italy, Argentina, Saudi Arabia, and Iran. The latter country's Blood Transfusion Organization has so far been unsuccessful in making the company make up for the damage, despite compensations it has paid to the patients.[8]

Business

Products

The company also produces a broad range of over-the-counter products, among them Allegra, IcyHot for muscle pain, Gold Bond for skin irritation, and Selsun Blue dandruff shampoo (these brands were acquired in 2010 when Sanofi-Aventis purchased Chattem).

Management

Stockholders

As of 31 January 2011:[1]

  • Breakdown of share ownership: 5.16% by Total, 9.02% by L'Oréal, 0.46% treasury shares and 1.43% employees. The remaining 83.93% are publicly traded.
  • Voting rights distribution: 8.89% to Total, 15.61% to L'Oréal, 2.33% to employees, and 73.17% to the public.

Head office

In January 2012, Sanofi moved its head office location to 54, rue La Boétie in the 8th arrondissement of Paris. This former mansion designed by architect René-Patouillard had previously been the head office of Alcatel-Lucent.

Sanofi's previous head office was located in the 13th arrondissement of Paris, 174 Avenue de France. The architecture of the head office is of the predominate style of the area surrounding the François Mitterrand Library. After Sanofi and Aventis merged, the employees at the former Aventis head office in Schiltigheim, Alsace moved to Paris.[11]

Collaborative research

In addition to internal research and development activities Sanofi is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[12][13] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[14]

In June 2010, Sanofi and the Charite University of Berlin signed a cooperation agreement for the research and development of medicines and therapies.[15]

On October 25, Sanofi said its earnings for the third quarter slumped as generic competitors ate into profits of its Eloxatin cancer treatment.[16]

Sanofi pasteur, vaccines division of Sanofi Group, awarded $97 Million HHS contract in 2005.[17]

Aventis Foundation

The Aventis Foundation,[18] a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. Its aim is to promote music, theater, art, literature, higher education and healthcare research.

See also

Paris portal
Companies portal

References

External links

  • Aventis Foundation
  • BIO IT world.com

Template:Euro Stoxx 50 Companies

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.